Last update
3/23/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 3 Researches
7.3
USERS' SCORE
Excellent
Based on 8 Reviews
9
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
N-acetyl-L-cysteine
600 mg
**
Top Medical Research Studies
8
We explored how N-acetylcysteine (NAC), a common mucolytic agent, plays a role in treating bronchitis associated with chronic obstructive pulmonary disease (COPD). This study focused on the treatable traits (TT) strategy, which aims to identify and manage specific traits of COPD that are clinically significant and manageable.
Our findings indicate that NAC is particularly valuable for patients experiencing a frequent productive cough, a common trait of bronchitis in COPD. Not only does it help reduce mucus buildup, but it also appears to have benefits for reducing airway inflammation and limitations in airflow.
Interestingly, the research highlights that NAC’s antioxidant and anti-inflammatory properties can support various symptoms linked to bronchitis. By adopting the TT strategy, including NAC in the treatment plan, we observed improvements in lung function and overall quality of life for patients, while minimizing unnecessary medication.
Thus, incorporating NAC into bronchitis management within the framework of personalized medicine shows promising potential to help patients manage their symptoms better and enhance their daily lives.
Our findings indicate that NAC is particularly valuable for patients experiencing a frequent productive cough, a common trait of bronchitis in COPD. Not only does it help reduce mucus buildup, but it also appears to have benefits for reducing airway inflammation and limitations in airflow.
Interestingly, the research highlights that NAC’s antioxidant and anti-inflammatory properties can support various symptoms linked to bronchitis. By adopting the TT strategy, including NAC in the treatment plan, we observed improvements in lung function and overall quality of life for patients, while minimizing unnecessary medication.
Thus, incorporating NAC into bronchitis management within the framework of personalized medicine shows promising potential to help patients manage their symptoms better and enhance their daily lives.
Read More
7
Our investigation delves into how N-acetylcysteine (NAC) impacts the treatment of bronchitis when used alongside phage therapy. We specifically looked at the interactions between NAC and certain bacterial strains known to cause lower respiratory tract infections.
Through our study, we discovered that NAC could act as an adjuvant, enhancing the effectiveness of phages in fighting these bacterial pathogens. Under certain conditions, NAC appeared to make bacteria more susceptible to phage infection, which could facilitate better treatment outcomes.
However, we also noted that the effectiveness of this combination depends on various factors, including the specific characteristics of the phages and the surrounding environment. Different outcomes were observed in terms of how phages interacted with bacteria, emphasizing the need for further research to fully understand this complex relationship.
Overall, this study provides insights into optimizing treatment strategies for bronchitis, especially in an era of rising antibiotic resistance, by combining mucoactive agents like NAC with innovative therapies such as phage therapy.
Through our study, we discovered that NAC could act as an adjuvant, enhancing the effectiveness of phages in fighting these bacterial pathogens. Under certain conditions, NAC appeared to make bacteria more susceptible to phage infection, which could facilitate better treatment outcomes.
However, we also noted that the effectiveness of this combination depends on various factors, including the specific characteristics of the phages and the surrounding environment. Different outcomes were observed in terms of how phages interacted with bacteria, emphasizing the need for further research to fully understand this complex relationship.
Overall, this study provides insights into optimizing treatment strategies for bronchitis, especially in an era of rising antibiotic resistance, by combining mucoactive agents like NAC with innovative therapies such as phage therapy.
Read More
7
We examined the effectiveness of n-acetyl-l-cysteine, a mucolytic agent, in treating patients with stable chronic obstructive pulmonary disease (COPD). In our analysis, we looked at randomized controlled trials which highlighted various mucolytics including n-acetyl-l-cysteine, ambroxol, and others.
While mucolytics like n-acetyl-l-cysteine showed promise in reducing exacerbations and hospitalizations among patients, it did not significantly improve other outcomes related to bronchitis or lung function, such as mortality or work absenteeism. The results suggested a reduction in the rate of exacerbations and a tendency towards better outcomes in those who experienced two or more exacerbations, yet no improvement was seen in overall lung function tests.
Importantly, the safety profile of mucolytics was comparable to that of a placebo, indicating that patients can tolerate this treatment without serious side effects. Overall, while we recognized some benefits, it is clear that n-acetyl-l-cysteine might not be a game changer for bronchitis management.
While mucolytics like n-acetyl-l-cysteine showed promise in reducing exacerbations and hospitalizations among patients, it did not significantly improve other outcomes related to bronchitis or lung function, such as mortality or work absenteeism. The results suggested a reduction in the rate of exacerbations and a tendency towards better outcomes in those who experienced two or more exacerbations, yet no improvement was seen in overall lung function tests.
Importantly, the safety profile of mucolytics was comparable to that of a placebo, indicating that patients can tolerate this treatment without serious side effects. Overall, while we recognized some benefits, it is clear that n-acetyl-l-cysteine might not be a game changer for bronchitis management.
Read More
Most Useful Reviews
10
Breath easier now
130 people found this helpful
Absolutely love it! If you suffer from asthma, COPD, chronic bronchitis, or feel a cold settling in your chest, take this! I’ve struggled with chronic allergies that escalate into chest issues. I started taking two daily for a couple of weeks to support my breathing. I hadn't been able to inflate a balloon for years without feeling dizzy! This past summer, I inflated multiple pool floats simultaneously; the only product I was using was N-Acetyl Cysteine. Each time I tested this product, I achieved positive results! I wholeheartedly recommend it for anyone facing breathing challenges. It's safe, affordable, and effective!
Read More
9
Excellent for bronchitis
15 people found this helpful
This treatment is like an emergency remedy for coughs and bronchitis. It significantly helps in clearing phlegm from the lungs, working better than other substitutes like ACC. It's particularly useful post-bronchitis and after illnesses such as COVID-19. Plus, it effectively detoxifies the body after a night of drinking. Highly recommend!
Read More
9
Rapid recovery
3 people found this helpful
I took this during my bronchitis treatment, and I believe it helped expedite my recovery. I recommend it.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 3 Researches
7.3
- All Researches
8
We explored how N-acetylcysteine (NAC), a common mucolytic agent, plays a role in treating bronchitis associated with chronic obstructive pulmonary disease (COPD). This study focused on the treatable traits (TT) strategy, which aims to identify and manage specific traits of COPD that are clinically significant and manageable.
Our findings indicate that NAC is particularly valuable for patients experiencing a frequent productive cough, a common trait of bronchitis in COPD. Not only does it help reduce mucus buildup, but it also appears to have benefits for reducing airway inflammation and limitations in airflow.
Interestingly, the research highlights that NAC’s antioxidant and anti-inflammatory properties can support various symptoms linked to bronchitis. By adopting the TT strategy, including NAC in the treatment plan, we observed improvements in lung function and overall quality of life for patients, while minimizing unnecessary medication.
Thus, incorporating NAC into bronchitis management within the framework of personalized medicine shows promising potential to help patients manage their symptoms better and enhance their daily lives.
Our findings indicate that NAC is particularly valuable for patients experiencing a frequent productive cough, a common trait of bronchitis in COPD. Not only does it help reduce mucus buildup, but it also appears to have benefits for reducing airway inflammation and limitations in airflow.
Interestingly, the research highlights that NAC’s antioxidant and anti-inflammatory properties can support various symptoms linked to bronchitis. By adopting the TT strategy, including NAC in the treatment plan, we observed improvements in lung function and overall quality of life for patients, while minimizing unnecessary medication.
Thus, incorporating NAC into bronchitis management within the framework of personalized medicine shows promising potential to help patients manage their symptoms better and enhance their daily lives.
Read More
7
Our investigation delves into how N-acetylcysteine (NAC) impacts the treatment of bronchitis when used alongside phage therapy. We specifically looked at the interactions between NAC and certain bacterial strains known to cause lower respiratory tract infections.
Through our study, we discovered that NAC could act as an adjuvant, enhancing the effectiveness of phages in fighting these bacterial pathogens. Under certain conditions, NAC appeared to make bacteria more susceptible to phage infection, which could facilitate better treatment outcomes.
However, we also noted that the effectiveness of this combination depends on various factors, including the specific characteristics of the phages and the surrounding environment. Different outcomes were observed in terms of how phages interacted with bacteria, emphasizing the need for further research to fully understand this complex relationship.
Overall, this study provides insights into optimizing treatment strategies for bronchitis, especially in an era of rising antibiotic resistance, by combining mucoactive agents like NAC with innovative therapies such as phage therapy.
Through our study, we discovered that NAC could act as an adjuvant, enhancing the effectiveness of phages in fighting these bacterial pathogens. Under certain conditions, NAC appeared to make bacteria more susceptible to phage infection, which could facilitate better treatment outcomes.
However, we also noted that the effectiveness of this combination depends on various factors, including the specific characteristics of the phages and the surrounding environment. Different outcomes were observed in terms of how phages interacted with bacteria, emphasizing the need for further research to fully understand this complex relationship.
Overall, this study provides insights into optimizing treatment strategies for bronchitis, especially in an era of rising antibiotic resistance, by combining mucoactive agents like NAC with innovative therapies such as phage therapy.
Read More
7
We examined the effectiveness of n-acetyl-l-cysteine, a mucolytic agent, in treating patients with stable chronic obstructive pulmonary disease (COPD). In our analysis, we looked at randomized controlled trials which highlighted various mucolytics including n-acetyl-l-cysteine, ambroxol, and others.
While mucolytics like n-acetyl-l-cysteine showed promise in reducing exacerbations and hospitalizations among patients, it did not significantly improve other outcomes related to bronchitis or lung function, such as mortality or work absenteeism. The results suggested a reduction in the rate of exacerbations and a tendency towards better outcomes in those who experienced two or more exacerbations, yet no improvement was seen in overall lung function tests.
Importantly, the safety profile of mucolytics was comparable to that of a placebo, indicating that patients can tolerate this treatment without serious side effects. Overall, while we recognized some benefits, it is clear that n-acetyl-l-cysteine might not be a game changer for bronchitis management.
While mucolytics like n-acetyl-l-cysteine showed promise in reducing exacerbations and hospitalizations among patients, it did not significantly improve other outcomes related to bronchitis or lung function, such as mortality or work absenteeism. The results suggested a reduction in the rate of exacerbations and a tendency towards better outcomes in those who experienced two or more exacerbations, yet no improvement was seen in overall lung function tests.
Importantly, the safety profile of mucolytics was comparable to that of a placebo, indicating that patients can tolerate this treatment without serious side effects. Overall, while we recognized some benefits, it is clear that n-acetyl-l-cysteine might not be a game changer for bronchitis management.
Read More
User Reviews
USERS' SCORE
Excellent
Based on 8 Reviews
9
- All Reviews
- Positive Reviews
- Negative Reviews
10
Breath easier now
130 people found this helpful
Absolutely love it! If you suffer from asthma, COPD, chronic bronchitis, or feel a cold settling in your chest, take this! I’ve struggled with chronic allergies that escalate into chest issues. I started taking two daily for a couple of weeks to support my breathing. I hadn't been able to inflate a balloon for years without feeling dizzy! This past summer, I inflated multiple pool floats simultaneously; the only product I was using was N-Acetyl Cysteine. Each time I tested this product, I achieved positive results! I wholeheartedly recommend it for anyone facing breathing challenges. It's safe, affordable, and effective!
Read More
9
Excellent for bronchitis
15 people found this helpful
This treatment is like an emergency remedy for coughs and bronchitis. It significantly helps in clearing phlegm from the lungs, working better than other substitutes like ACC. It's particularly useful post-bronchitis and after illnesses such as COVID-19. Plus, it effectively detoxifies the body after a night of drinking. Highly recommend!
Read More
9
Rapid recovery
3 people found this helpful
I took this during my bronchitis treatment, and I believe it helped expedite my recovery. I recommend it.
Read More
7.5
Strong recommendation
1 people found this helpful
I gave NAC to a sick friend with bronchitis. After using it, both she and her mother felt better post-coronavirus! It’s superior to other pharmacy alternatives. Highly recommended!
Read More
7.5
Immune support noted
1 people found this helpful
Very good! It supports the immune system against bronchitis and improves overall well-being. The benefits were evident by the second week for me. Everything else is fine.
Read More
Frequently Asked Questions
7.5
Immune support noted
1 people found this helpful
Very good! It supports the immune system against bronchitis and improves overall well-being. The benefits were evident by the second week for me. Everything else is fine.
9
Rapid recovery
3 people found this helpful
I took this during my bronchitis treatment, and I believe it helped expedite my recovery. I recommend it.
9
Excellent for bronchitis
15 people found this helpful
This treatment is like an emergency remedy for coughs and bronchitis. It significantly helps in clearing phlegm from the lungs, working better than other substitutes like ACC. It's particularly useful post-bronchitis and after illnesses such as COVID-19. Plus, it effectively detoxifies the body after a night of drinking. Highly recommend!
7.5
Strong recommendation
1 people found this helpful
I gave NAC to a sick friend with bronchitis. After using it, both she and her mother felt better post-coronavirus! It’s superior to other pharmacy alternatives. Highly recommended!
8
We explored how N-acetylcysteine (NAC), a common mucolytic agent, plays a role in treating bronchitis associated with chronic obstructive pulmonary disease (COPD). This study focused on the treatable traits (TT) strategy, which aims to identify and manage specific traits of COPD that are clinically significant and manageable.
Our findings indicate that NAC is particularly valuable for patients experiencing a frequent productive cough, a common trait of bronchitis in COPD. Not only does it help reduce mucus buildup, but it also appears to have benefits for reducing airway inflammation and limitations in airflow.
Interestingly, the research highlights that NAC’s antioxidant and anti-inflammatory properties can support various symptoms linked to bronchitis. By adopting the TT strategy, including NAC in the treatment plan, we observed improvements in lung function and overall quality of life for patients, while minimizing unnecessary medication.
Thus, incorporating NAC into bronchitis management within the framework of personalized medicine shows promising potential to help patients manage their symptoms better and enhance their daily lives.
Our findings indicate that NAC is particularly valuable for patients experiencing a frequent productive cough, a common trait of bronchitis in COPD. Not only does it help reduce mucus buildup, but it also appears to have benefits for reducing airway inflammation and limitations in airflow.
Interestingly, the research highlights that NAC’s antioxidant and anti-inflammatory properties can support various symptoms linked to bronchitis. By adopting the TT strategy, including NAC in the treatment plan, we observed improvements in lung function and overall quality of life for patients, while minimizing unnecessary medication.
Thus, incorporating NAC into bronchitis management within the framework of personalized medicine shows promising potential to help patients manage their symptoms better and enhance their daily lives.
7
We examined the effectiveness of n-acetyl-l-cysteine, a mucolytic agent, in treating patients with stable chronic obstructive pulmonary disease (COPD). In our analysis, we looked at randomized controlled trials which highlighted various mucolytics including n-acetyl-l-cysteine, ambroxol, and others.
While mucolytics like n-acetyl-l-cysteine showed promise in reducing exacerbations and hospitalizations among patients, it did not significantly improve other outcomes related to bronchitis or lung function, such as mortality or work absenteeism. The results suggested a reduction in the rate of exacerbations and a tendency towards better outcomes in those who experienced two or more exacerbations, yet no improvement was seen in overall lung function tests.
Importantly, the safety profile of mucolytics was comparable to that of a placebo, indicating that patients can tolerate this treatment without serious side effects. Overall, while we recognized some benefits, it is clear that n-acetyl-l-cysteine might not be a game changer for bronchitis management.
While mucolytics like n-acetyl-l-cysteine showed promise in reducing exacerbations and hospitalizations among patients, it did not significantly improve other outcomes related to bronchitis or lung function, such as mortality or work absenteeism. The results suggested a reduction in the rate of exacerbations and a tendency towards better outcomes in those who experienced two or more exacerbations, yet no improvement was seen in overall lung function tests.
Importantly, the safety profile of mucolytics was comparable to that of a placebo, indicating that patients can tolerate this treatment without serious side effects. Overall, while we recognized some benefits, it is clear that n-acetyl-l-cysteine might not be a game changer for bronchitis management.
7
Our investigation delves into how N-acetylcysteine (NAC) impacts the treatment of bronchitis when used alongside phage therapy. We specifically looked at the interactions between NAC and certain bacterial strains known to cause lower respiratory tract infections.
Through our study, we discovered that NAC could act as an adjuvant, enhancing the effectiveness of phages in fighting these bacterial pathogens. Under certain conditions, NAC appeared to make bacteria more susceptible to phage infection, which could facilitate better treatment outcomes.
However, we also noted that the effectiveness of this combination depends on various factors, including the specific characteristics of the phages and the surrounding environment. Different outcomes were observed in terms of how phages interacted with bacteria, emphasizing the need for further research to fully understand this complex relationship.
Overall, this study provides insights into optimizing treatment strategies for bronchitis, especially in an era of rising antibiotic resistance, by combining mucoactive agents like NAC with innovative therapies such as phage therapy.
Through our study, we discovered that NAC could act as an adjuvant, enhancing the effectiveness of phages in fighting these bacterial pathogens. Under certain conditions, NAC appeared to make bacteria more susceptible to phage infection, which could facilitate better treatment outcomes.
However, we also noted that the effectiveness of this combination depends on various factors, including the specific characteristics of the phages and the surrounding environment. Different outcomes were observed in terms of how phages interacted with bacteria, emphasizing the need for further research to fully understand this complex relationship.
Overall, this study provides insights into optimizing treatment strategies for bronchitis, especially in an era of rising antibiotic resistance, by combining mucoactive agents like NAC with innovative therapies such as phage therapy.
References
- Sui B, Li X, Li N, Tao Y, Wang L, et al. Synergistic action of mucoactive drugs and phages against and . Microbiol Spectr. 2025;13:e0160124. 10.1128/spectrum.01601-24
- Scioscia G, Baraldi F, Bigoni T, Papi A, Vatrella A, et al. The precision medicine strategy to treat COPD pulmonary traits in clinical practice: The role of N-acetylcysteine. Respir Med. 2024;235:107865. 10.1016/j.rmed.2024.107865
- Ohnishi H, Tanimoto T, Inaba R, Eitoku M. Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Investig. 2024;62:1168. 10.1016/j.resinv.2024.10.004
Data last updated:
